Novozymes (CPSE:NSIS B) Launches Optiva Triticum As Valuation Debate Stays In Focus
Novozymes (CPSE:NSIS B) drew fresh attention on 12 August 2026 after Novonesis launched Optiva Triticum, a biosolution designed to give pasta producers more flexibility in wheat sourcing while preserving texture and firmness.
See our latest analysis for Novozymes.
At a share price of DKK424.6, Novozymes has seen a 12.27% 90 day share price return and a 49.03% three year total shareholder return. This may point to momentum that product launches like Optiva Triticum may be influencing as investors reassess growth potential and risks.
If this kind of product driven story interests you, it is a good moment to look beyond Novozymes and see what stands out in our 104 top founder-led companies
Recent gains and new products like Optiva Triticum give bulls a growth story to point to, while bears focus on valuation risk. How Novozymes current pricing and cash generation history should be viewed is an important consideration as you evaluate the stock.
Most Popular Narrative: 6.2% Overvalued
The most followed narrative puts Novozymes fair value at DKK400, slightly below the DKK424.6 last close, which helps explain debate around the current share price.
Although emerging markets are delivering double-digit volume growth helped by local labs and commercial teams, intensifying regional competition and potential regulatory hurdles in key countries could slow incremental share gains and cap the pace of top line expansion and operating leverage. This may limit upside to revenue growth and EBITDA margin.
Want to see what sits behind that growth ceiling? The narrative leans on specific revenue paths, margin shifts and a future earnings multiple that is anything but conservative.
Result: Fair Value of DKK400 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear risks that could unsettle this Novozymes narrative, including tougher emerging market competition and slower than expected regulatory progress for probiotics in China.
Find out about the key risks to this Novozymes narrative.
Another View on Novozymes Valuation
The bearish narrative suggests Novozymes is 6.2% overvalued at around DKK424.6 versus a DKK400 fair value. Yet the SWS DCF model points in a different direction and puts intrinsic value closer to DKK647.73, implying the stock trades at a 34.4% discount. Which lens fits your expectations better?
For a closer look at how this cash flow view is built, including the assumptions behind discount rates and growth, take a moment to review the Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Novozymes for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 257 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this mix of optimism and caution around Novozymes feels familiar, it may be a good time to review the data for yourself and weigh both sides. Start by checking the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Novozymes?
If you are serious about finding the next opportunity after Novozymes, the right screeners can quickly surface stocks that fit the risk and return profile you prefer.
- Spot underappreciated potential by checking companies that combine quality with attractive pricing through the 257 high quality undervalued stocks.
- Prioritise resilience by scanning for companies that show strong financial footing using the solid balance sheet and fundamentals stocks screener (435 results).
- Hunt for tomorrow's standouts by filtering for lesser known companies with strong fundamentals in the screener containing 608 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com